Abrogation of cisplatin-induced nephrotoxicity by emodin in rats

Fundamental and Clinical Pharmacology

Volumn 27, Issue 2, 2013, Pages 192-200

  Ali, Badreldin H ^a   Al Salam, Suhail ^b   Al Husseini, Isehaq S ^a   Al Lawati, Intisar ^a   Waly, Mostafa ^a   Yasin, Javed ^b   Fahim, Mohamed ^b   Nemmar, Abderrahim ^b  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Cisplatin; Emodin; Nephrotoxicity; Rats

Indexed keywords

CISPLATIN; CREATININE; EMODIN; N ACETYL BETA GLUCOSAMINIDASE; SUPEROXIDE DISMUTASE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; DRUG INDUCED DISEASE; ENZYME ACTIVITY; HISTOPATHOLOGY; KIDNEY INJURY; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; URINALYSIS;

ACETYLGLUCOSAMINIDASE; ANIMALS; CISPLATIN; CREATININE; DRUG INTERACTIONS; EMODIN; GLUTATHIONE; KIDNEY CORTEX; KIDNEY TUBULES, PROXIMAL; MALE; NECROSIS; OSMOLAR CONCENTRATION; RANDOM ALLOCATION; RATS; RATS, WISTAR; RENAL INSUFFICIENCY; SUPEROXIDE DISMUTASE; UREA;

EID: 84874384385     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.01003.x     Document Type: Article

References (37)

1. Moncharmont C., Auberdiac P., Mélis A. et al. Cisplatin or carboplatin, that is the question. Bull. Cancer (2011) 98 164-175.
2. Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. (2007) 334 115-124.
3. Zhang L., Hanigan M.H. Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin. J. Pharmacol. Exp. Ther. (2003) 306 988-994.
4. Wainford R.D., Weaver R.J., Stewart K.N., Brown P., Hawksworth G.M. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology (2008) 249 184-193.
5. Perazella M.A., Moeckel G.W. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin. Nephrol. (2010) 30 570-581.
6. Chirino Y.I., Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp. Toxicol. Pathol. (2009) 61 223-242.
7. Pabla N., Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. (2008) 73 994-1007.
8. Ali B.H., Al Moundhri M.S. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem. Toxicol. (2006) 44 1173-1183.
9. Chang Y.C., Lai T.Y., Yu C.S. et al. Emodin induces apoptotic death in murine myelomonocytic leukemia WEHI-3 cells in vitro and enhances phagocytosis in leukemia mice in vivo. Evid. Based Complement. Alternat. Med. (2011) 2011 523596.
10. Liu A., Chen H., Wei W. et al. Antiproliferative and antimetastatic effects of emodin on human pancreatic cancer. Oncol. Rep. (2011) 26 81-89.
11. Yon J.M., Baek I.J., Lee B.J., Yun Y.W., Nam S.Y. Emodin and [6]-gingerol lessen hypoxia-induced embryotoxicities in cultured mouse whole embryos via upregulation of hypoxia-inducible factor 1α and intracellular superoxide dismutases. Reprod. Toxicol. (2011) 31 513-518.
12. Wang W., Sun Y.P., Huang X.Z. et al. Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathione depletion and MRP1 downregulation. Biochem. Pharmacol. (2010) 79 1134-1140.
13. Dang S.S., Zhang X., Jia X.L. et al. Protective effects of emodin and astragalus polysaccharides on chronic hepatic injury in rats. Chin. Med. J. (Engl.) (2008) 121 1010-1014.
14. Li Y.H., He F.Q., Huang Z.W., Xue P., Xia Q. Protective effects of emodin on intestinal lesion in rat model with acute necrotizing pancreatitis. Sichuan Da Xue Xue Bao Yi Xue Ban (2010) 41 1012-1015.
15. Mizuno M., Kawamura H., Ishizuka Y., Sotoyama H., Nawa H. The anthraquinone derivative emodin attenuates methamphetamine-induced hyperlocomotion and startle response in rats. Pharmacol. Biochem. Behav. (2010) 97 392-398.
16. Mizuno M., Kawamura H., Takei N., Nawa H. The anthraquinone derivative emodin ameliorates neurobehavioral deficits of a rodent model for schizophrenia. J. Neural. Transm. (2008) 115 521-530.
17. Ding Y., Zhao L., Mei H. et al. Exploration of emodin to treat alpha-naphthylisothiocyanate-induced cholestatic hepatitis via anti-inflammatory pathway. Eur. J. Pharmacol. (2008) 590 377-386.
18. Ali B.H., Al Moundhri M.S., Tag Eldin M., Nemmar A., Tanira M.O. The ameliorative effect of cysteine prodrug L-2-oxothiazolidine-4-carboxylic acid on cisplatin-induced nephrotoxicity in rats. Fundam. Clin. Pharmacol. (2007) 21 547-553.
19. Waly M.I., Al Moundhri M.S., Ali B.H. Effect of curcumin on cisplatin- and oxaliplatin-induced oxidative stress in human embryonic kidney (HEK) 293 cells. Ren. Fail. (2011) 33 518-523.
20. Ali B.H., Al-Moundhri M., Eldin M.T., Nemmar A., Al-Siyabi S., Annamalai K. Amelioration of cisplatin-induced nephrotoxicity in rats by tetramethylpyrazine, a major constituent of the Chinese herb Ligusticum wallichi. Exp. Biol. Med. (Maywood) (2008) 233 891-896.
21. Vielhauer V., Stavrakis G., Mayadas T.N. Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J. Clin. Invest. (2005) 115 1199-1209.
22. Ali B.H., Abdelrahman A.M., Al-Salam S. et al. The effect of sildenafil on cisplatin nephrotoxicity in rats. Basic Clin. Pharmacol. Toxicol. (2011) 109 300-308.
23. Lee J., Jung E., Lee J. et al. Emodin inhibits TNF alpha-induced MMP-1 expression through suppression of activator protein-1 (AP-1). Life Sci. (2006) 79 2480-2485.
24. Launay-Vacher V., Rey J.B., Isnard-Bagnis C., Deray G., Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother. Pharmacol. (2008) 61 903-909.
25. Nemmar A., Al-Salam S., Zia S., Yasin J., Al Husseni I., Ali B.H. Diesel exhaust particles in the lung aggravate experimental acute renal failure. Toxicol. Sci. (2010) 113 267-277.
26. Saito H. Pathophysiological regulation of renal SLC22A organic ion transporters in acute kidney injury: pharmacological and toxicological implications. Pharmacol. Ther. (2010) 125 79-91.
27. Al Suleimani Y.M., Abdelrahman A.M., AlMahruqi A.S. et al. Interaction of nimesulide, a cyclooxygenase-2 inhibitor, with cisplatin in normotensive and spontaneously hypertensive rats. Food Chem. Toxicol. (2010) 48 139-144.
28. Cabezos P.A., Vera G., Martín-Fontelles M.I., Fernández-Pujol R., Abalo R. Cisplatin-induced gastrointestinal dysmotility is aggravated after chronic administration in the rat. Comparison with pica. Neurogastroenterol. Motil. (2010) 22 797-805.
29. Shaw M. Cell-specific biomarkers in renal medicine and research. Methods Mol. Biol. (2010) 641 271-302.
30. Vera G., Chiarlone A., Martín M.I., Abalo R. Altered feeding behaviour induced by long-term cisplatin in rats. Auton. Neurosci. (2006) 127 81-92.
31. Conklin K.A. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr. Cancer (2000) 37 1-18.
32. Clark J.S., Faisal A., Baliga R., Nagamine Y., Arany I. Cisplatin induces apoptosis through the ERK-p66shc pathway in renal proximal tubule cells. Cancer Lett. (2010) 297 165-170.
33. Burger H., Loos W.J., Eechoute K., Verweij J., Mathijssen R.H., Wiemer E.A. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist. Updat. (2011) 14 22-34.
34. Yonezawa A., Inui K. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem. Pharmacol. (2011) 81 563-568.
35. Bhadauria M. Dose-dependent hepatoprotective effect of emodin against acetaminophen-induced acute damage in rats. Exp. Toxicol. Pathol. (2010) 62 627-635.
36. Hanigan M.H., Townsend D.M., Cooper A.J. Metabolism of cisplatin to a nephrotoxin. Toxicology (2009) 257 174-175.
37. Heo S.K., Yun H.J., Noh E.K., Park S.D. Emodin and rhein inhibit LIGHT-induced monocytes migration by blocking of ROS production. Vascul. Pharmacol. (2010) 53 28-37.